Amarin Corp. (Nasdaq: AMRN) reported positive results from a Phase III clinical trial of its very high triglyceride treatment AMR101 sending the stock price soaring $1.93 to $5.48.
Amarin Reports Upbeat Trial Results
November 29, 2010 at 11:43 AM EST